Literature DB >> 9681073

From the R.E.A.L. Classification to the upcoming WHO scheme: a step toward universal categorization of lymphoma entities?

S A Pileri1, M Milani, G Fraternali-Orcioni, E Sabattini.   

Abstract

Entities:  

Mesh：

Year:  1998        PMID： 9681073     DOI： 10.1023/a:1008278706002

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  9 in total

1.  Predictors of survival after a diagnosis of non-Hodgkin lymphoma in a resource-limited setting: a retrospective study on the impact of HIV infection and its treatment.

Authors:  Moses H Bateganya; Jeffrey Stanaway; Paula E Brentlinger; Amalia S Magaret; Anna Wald; Jackson Orem; Corey Casper
Journal:  J Acquir Immune Defic Syndr       Date:  2011-04       Impact factor: 3.731

Review 2.  Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.

Authors:  Aude Collignon; Anne Wanquet; Elsa Maitre; Edouard Cornet; Xavier Troussard; Thérèse Aurran-Schleinitz
Journal:  Curr Oncol Rep       Date:  2017-04       Impact factor: 5.075

3.  Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie.

Authors:  Marlene Troch; Barbara Kiesewetter; Wolfgang Willenbacher; Ella Willenbacher; Armin Zebisch; Werner Linkesch; Michael Fridrik; Leonhard Müllauer; Richard Greil; Markus Raderer
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

4.  111In-DOTA- dPhe1-Tyr3-octreotide, 111In-DOTA-lanreotide and 67Ga citrate scintigraphy for visualisation of extranodal marginal zone B-cell lymphoma of the MALT type: a comparative study.

Authors:  Shuren Li; Amir Kurtaran; Mei Li; Tatjana Traub-Weidinger; Oskar Kienast; Wolfgang Schima; Peter Angelberger; Irene Virgolini; Markus Raderer; Robert Dudczak
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-24       Impact factor: 9.236

5.  A phase II study of bortezomib in patients with MALT lymphoma.

Authors:  Marlene Troch; Constanze Jonak; Leonhard Müllauer; Andreas Püspök; Michael Formanek; Wolfgang Hauff; Christoph C Zielinski; Andreas Chott; Markus Raderer
Journal:  Haematologica       Date:  2009-03-31       Impact factor: 9.941

6.  Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type.

Authors:  M Raderer; T Traub; M Formanek; I Virgolini; C Osterreicher; W Fiebiger; M Penz; U Jäger; J Pont; A Chott; A Kurtaran
Journal:  Br J Cancer       Date:  2001-11-16       Impact factor: 7.640

7.  Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma.

Authors:  M Raderer; F Vorbeck; M Formanek; C Osterreicher; J Valencak; M Penz; G Kornek; G Hamilton; B Dragosics; A Chott
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

8.  Susceptibility loci associated with specific and shared subtypes of lymphoid malignancies.

Authors:  Joseph Vijai; Tomas Kirchhoff; Kasmintan A Schrader; Jennifer Brown; Ana Virginia Dutra-Clarke; Christopher Manschreck; Nichole Hansen; Rohini Rau-Murthy; Kara Sarrel; Jennifer Przybylo; Sohela Shah; Srujana Cheguri; Zsofia Stadler; Liying Zhang; Ora Paltiel; Dina Ben-Yehuda; Agnes Viale; Carol Portlock; David Straus; Steven M Lipkin; Mortimer Lacher; Mark Robson; Robert J Klein; Andrew Zelenetz; Kenneth Offit
Journal:  PLoS Genet       Date:  2013-01-17       Impact factor: 5.917

9.  Concurrent colonic mucosa-associated lymphoid tissue lymphoma and adenoma diagnosed after a positive fecal occult blood test: a case report.

Authors:  Pei-Chiang Lin; Jinn-Shiun Chen; Po Deng; Chih-Wei Wang; Chiung-Huei Huang; Reiping Tang; Jy-Ming Chiang; Chien-Yuh Yeh; Pao-Shiu Hsieh; Wen-Sy Tsai; Sum-Fu Chiang
Journal:  J Med Case Rep       Date:  2016-01-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.